Clinical Review

Testicular Cancer: Diagnosis and Treatment

Author and Disclosure Information

 

References

Conclusion

Testicular cancer is the most common cancer afflicting young men. Prompt diagnostic workup initiated in a primary care or hospital setting followed by a referral to a multidisciplinary team of urologists, medical oncologists, and radiation oncologists enables cure in a majority of patients. For patients with stage I seminoma, a radical inguinal orchiectomy followed by active surveillance may offer the best long-term outcome with minimal side effects. For patients with relapsed/refractory testicular cancers, clinical trial participation is strongly encouraged. Patients with a history of testicular cancer benefit from robust survivorship care tailored to their prior therapies. This can be safely delivered through their primary care providers in collaboration with the multidisciplinary oncology team.

Pages

Recommended Reading

Enzalutamide in castration-sensitive prostate cancer and ctDNA to monitor early colorectal cancer
MDedge Hematology and Oncology
Equal access to care for black men lowers risk of prostate cancer-specific mortality
MDedge Hematology and Oncology
Trial matches pediatric cancer patients to targeted therapies
MDedge Hematology and Oncology
Short-term ADT improves radiation salvage after prostatectomy
MDedge Hematology and Oncology
TITAN trial yields big survival benefits in mCSPC
MDedge Hematology and Oncology
ENZAMET trial: Early enzalutamide delays progression, improves survival in mHSPC
MDedge Hematology and Oncology
Novel enfortumab vedotin induces responses in advanced urothelial cancers
MDedge Hematology and Oncology
Nephrectomy may benefit select renal cancer patients based on risk factors
MDedge Hematology and Oncology
FDA approves bevacizumab-bvzr for several cancers
MDedge Hematology and Oncology
Specific prednisone regimen safer than others when used with abiraterone for mCR prostate cancer
MDedge Hematology and Oncology